Outcome of the Board Meeting and submission of Unaudited Financial Results of the Company for the quarter ended 30th June 2026

10th August 2026 IOLCP/CGC/2026 National Stock Exchange of India Ltd BSE Limited Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E) Dalal Street Mumbai - 400 051 Mumbai – 400 001 Security Symbol: IOLCP Security Code: 524164 Subject: Outcome of the Board Meeting and submission of Unaudited Financial Results of the Company for the quarter ended 30th June 2026 Dear Sir, Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. 10th August 2026, inter alia, considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June 2026. A copy of the aforesaid Financial Results, along with the Limited Review Reports issued by the Statutory Auditors, is enclosed herewith. We hereby confirm and declare that the Limited Review Reports issued by the Statutory Auditors on the Standalone and Consolidated Financial Results of the Company for the quarter ended 30th June 2026 contain an unmodified conclusion. The meeting of the Board of Directors commenced at 12:30 PM and concluded at 2:05 PM. The above Un-Audited Financial Results are also available on the website of the Company i.e. www.iolcp.com This is for your information & record. Thanking You, Yours faithfully, For IOL Chemicals and Pharmaceuticals Limited Abhay Raj Singh Sr. Vice President & Company Secretary 226-a, tagore nagar, ludhiana, punjab - 141001 ashwani associates & voice : +91-161-2301394, +91-161-4500426 facsimile: +91-161-2302083 chartered accountants mail : aditya@ashwaniassociates.in web :www.ashwaniassociates.in Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,_as amended Review Report to The Board ofDirectors IOL Chemicals and Pharmaceuticals Limited I. We have reviewed the accompanying statement ofunaudited standalone financial results ofMis IOL Chemicals and Pharmaceuticals Limited (the "Company") for the quarter ended 30" June ,2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements ofRegulation 33 ofthe SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "ListingRegulations"). 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusiononthe Statement basedon our review. 3. We conducted our review ofthe Statement in accordance withthe Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor ofthe Entity", issuedbythe Institute ofCharteredAccountants ofIndia. This standardrequires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data. A review is substantially less in scope than an audit conducted in accordance with Standard on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express anaudit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid IndianAccounting Standards ('IndAS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms ofthe Listing Regulations, including the manner in which it is to be disclosed, or that itcontains anymaterial misstatement. For Ashwani & Associates Chartered Accountants Firm Re" )0497N "VI"8· Arvind Ja Partner Place: Ludhiana M. No.: 097549 UDIN: 2c0171410xRTQ233 Dated:10.08.2026 IOL CHEMICALS AND PHARMACEUTICALS LIMITED STANDALONE UNAUDITED FINANCIAL RESULTS FORTHE QUARTER ENDED 30-JUNE-2026 in z Crore Quarter ended Year ended Sr. Particulars No. 30-Jun-2026 31-Mar-2026 30-Jun-2025 31-Mar-2026 (Unaudited) (Refer Note 3) (Unaudited) (Audited) Income: I Revenuefrom operations 756.26 619.45 551.69 2,319.06 II Other Income 8.18 1.74 7.37 21.28 Ill Total income (1+11) 764.44 621.19 559.06 2,340.34 IV Expenses: Cost of materials consumed 506.76 401.66 376.55 1,501.61 Purchases of stock-in-trade 0.75 3.83 - 4.02 Changes in inventories of finished goods, work- (29.53) (33.23) (12.32) (18.53) in-proaress and stock in trade Emplovee benefits expense 71.21 70.33 57.65 248.26 Financecosts 3.64 3.21 4.23 14.55 Depreciation and amortization expenses 21.32 20.27 19.75 80.17 Otherexpenses 103.52 84.29 67.66 314.61 Total Expenses (IV) 677.67 550.36 513.52 2,144.69 V Profit before exceptional items and tax (III-IV) 86.77 70.83 45.54 195.65 VI Exceptional items (refernote-3) - - - 11.21 VII Profit beforetax (V-VI) 86.77 70.83 45.54 184.44 VIII Tax Expense: Current tax 21.73 15.12 10.49 40.55 Deferred tax 0.56 2.53 1.09 6.17 Total taxexpense 22.29 17.65 11.58 46.72 IX Profit forthe period (VII-VIII) 64.48 53.18 33.96 137.72 X Other Comprehensive Income A(i) Items that will not be reclassified to profit or loss (1.35) 2.67 (1.90) 2.57 Income tax relating to items that will not be (ii) 0.34 (0.68) 0.48 (0.65) reclassified to profitor loss B (0) Items that will be reclassified to profit or loss (0.03) 0.96 1.04 0.91 (ii) Income tax relating to items that will be 0.01 (0.24) (0.26) (0.23) reclassified to profit orloss XI Total Comprehensive Incomeforthe period 63.45 55.89 33.32 140.32 (IX+X) XII Paid-upequity share capital 58.71 58.71 58.71 58.71 (Facevalue 2/- pershare) XIII Other equity (Reserves excluding revaluation 1,803.12 1,739.67 1,662.02 1,739.67 reserve) Earning per equity share of 2/- each (for continuing and discontinued operations) (not annualised except forthe year ended 31-Mar-2026) Basic and Diluted z 2.20 1.81 1.16 4.69 ?hartna 0Awl.l Head Office : 85, Industrial Area 'A',Ludhiana-141003 State - \t~Ind.ia. r-.... L24ll6PBl986PLC007030 Ph. : +91-161-4560500 Fax : +91-161-2608784 email : contact [p.com? 'ebsite : www.iolcp.com Regd. Office: Villagge & Post Office Handiayva,Fatehggaarh ChannaRoad, Barala-148107,PunJjab, India. Works: VillageFatehgarh Channa, MansaRoad (Trident Complex) District- Bamala-148101 State - Punjab, India. Ph. : +9l-1679-285285-86 Fax: +91-1679-285292 IOL CHEMICALS AND PHARMACEUTICALS LIMITED STANDALONE SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES in Crore Quarter ended Year ended Sr.No. Particulars 30-Jun-2026 31-Mar-2026 30-Jun-2025 31-Mar-2026 (Unaudited) (Refer Note 3) (Unaudited) (Audited) 4 Seament Revenue 'Net sale/income) - Pharmaceutical 469.49 374.51 329.33 1,396.25 - Chemical 364.96 306.42 281.06 1,160.53 - Unallocated 8.18 1.74 7.37 21.28 Total 842.63 682.67 617.76 2,578.06 Less : Inter seament revenue 78.19 61.48 58.70 237.72 Netsales/incomefrom operations 764.44 621.19 559.06 2,340.34 2 Seament Results Profit before tax and interest (from each seament) - Pharmaceutical 68.81 62.23 40.09 [Showing first 8,000 characters — download PDF for full document]